Division
DTMC
HEAL Study
No
Investigator(s)
Reese Jones, M.D.
Title
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine
Short Description
In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Release Date
May 23, 2017
Description

This 7-day double-blind, parallel-group, placebo-controlled inpatient study will compare the effects of 15 mg of intravenous methamphetamine given 60 hours before and 12 hours after a single oral dose of reserpine (0.5 or 1.0 mg) or placebo.

Keywords
interaction
methamphetamine
phase 1a
reserpine
stimulant
Assessments
Addiction Research Center Inventory
Brief Substance Craving Scale
Change in Sexual Function Questionnaire
ECG Monitoring
McLean Hospital Event Overt Aggression Checklist
Systematic Assessment for Treatment Emergent Effects
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
CPU-0006 Data
Study Links
ClinicalTrials.gov Link
CPU-0006 in NIH clinical trials registry
Study Documents
Protocol
CPU0006-Protocol.pdf
Dictionary
CPU0006-Dictionary.xlsx
Case Report Form(s)
CPU0006-CRF.pdf
Deidentification Notes
CPU0006-DeidentificationNotes.pdf
Nulled Values
CPU0006-NulledValues.csv
All Documents
CPU0006-AllDocuments.zip
Division
DTMC
HEAL Study
No
Investigator(s)
Louis Cantilena, Jr., M.D, Ph.D.
Title
Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
Short Description
This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous (i.v.) cocaine and RPR 102681 administered in 3 escalating doses.
Release Date
May 23, 2017
Description

The primary objective of this study is to determine if there are significant interactions between RPR 102681 treatment concurrent with i.v. cocaine infusions of 0 and 40 mg by measuring adverse events and cardiovascular responses [heart rate (HR), blood pressure (BP), and electrocardiogram (ECG)].

Keywords
cocaine
interaction
phase 1b
rpr102681
stimulant
Assessments
Addiction Research Center Inventory
Beck Depression Inventory
Blood Cocaine Level
Blood Study Agent Level
Brief Psychiatric Rating Scale
Brief Substance Craving Scale
Brief Symptom Inventory
ECG Monitoring
Profile of Mood States
Visual Analog Scales
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
CPU-0003 Data
Study Links
ClinicalTrials.gov Link
CPU-0003 in NIH clinical trials registry
Study Documents
Protocol
CPU0003-Protocol.pdf
Dictionary
CPU0003-Dictionary.xlsx
Case Report Form(s)
CPU0003-CRF.pdf
Deidentification Notes
CPU0003-DeidentificationNotes.pdf
Nulled Values
CPU0003-NulledValues.csv
All Documents
CPU0003-AllDocuments.zip
Division
DTMC
HEAL Study
No
Investigator(s)
Louis Cantilena, Jr., M.D, Ph.D.
Title
Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers
Short Description
To assess the safety, tolerance, and pharmacokinetics of multiple escalating dosages of oral GBR 12909 in cocaine experienced volunteers.
Release Date
May 23, 2017
Description

This is a human laboratory study that will assess the clinical pharmacology, safety and tolerance of three escalating oral doses of GBR 12909, which is 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride, in cocaine experienced volunteers.

Keywords
cocaine
gbr12909
interaction
phase 1a
stimulant
Assessments
Addiction Research Center Inventory
Blood Study Agent Level
Brief Substance Craving Scale
Change in Sexual Function Questionnaire
ECG Monitoring
McLean Hospital Event Overt Aggression Checklist
Systematic Assessment for Treatment Emergent Effects
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
CPU-0002 Data
Study Links
ClinicalTrials.gov Link
CPU-0002 in NIH clinical trials registry
Study Documents
Protocol
CPU0002-Protocol.pdf
Dictionary
CPU0002-Dictionary.xlsx
Case Report Form(s)
CPU0002-CRF.pdf
Deidentification Notes
CPU0002-DeidentificationNotes.pdf
Nulled Values
CPU0002-NulledValues.csv
All Documents
CPU0002-AllDocuments.zip

Immediate Memory Task/Delayed Memory Task

Submitted by administrator on
Abbreviation
IMT/DMT
Description

The IMT/DMT (Dougherty, Marsh, & Mathias, 2002) is a continuous performance test that was designed to assess impulsive behavior. The Immediate Memory Task involves comparison of consecutively presented numbers and responding in those instances when the current number matches the number immediately before it (called a correct detection). The Delayed Memory Task similarly involves responding to matching numbers, but the numbers to be compared are separated by a filler sequence (e.g. 12345).

Category
Impulsivity and General Trait & Behavior Scales
Subscribe to